Gain Therapeutics
GANX
16 hedge funds and large institutions have $3.87M invested in Gain Therapeutics in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.73% less ownership
Funds ownership: 9.78% → 9.05% (-0.73%)
19% less capital invested
Capital invested by funds: $4.75M → $3.87M (-$879K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$114K |
| 2 |
BlackRock
New York
|
+$44.5K |
| 3 |
CC
Cannell Capital
Alta,
Wyoming
|
+$9.49K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$7.97K |
| 5 |
HI
Hoey Investments
Coatesville,
Pennsylvania
|
+$1.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TI
Telemetry Investments
New York
|
-$276K |
| 2 |
V
Veritable
Wilmington,
Delaware
|
-$103K |
| 3 |
Jane Street
New York
|
-$48K |
| 4 |
Millennium Management
New York
|
-$44K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$37.9K |
GANX Hedge Fund Activity: Q2 2022 in Review
16 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Gain Therapeutics (GANX) for Q2 2022, worth a combined $3.87M — down 19% from $4.75M a quarter earlier.
Fund positioning in GANX was balanced in Q2 2022: 3 funds opened new positions, 3 closed out, 6 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $114K. The largest seller was Telemetry Investments, cutting an estimated $276K.
- 16 institutional investors held Gain Therapeutics (GANX) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $3.87M of Gain Therapeutics stock for Q2 2022, down 19% quarter-over-quarter.
- 3 funds opened new Gain Therapeutics positions in Q2 2022 and 3 closed out, a net change of 0 holders.
- The largest Gain Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $114K added.
- The largest Gain Therapeutics seller in Q2 2022 was Telemetry Investments, an estimated $276K sold.
Based on aggregated 13F filings for Q2 2022.